title: [Prospective and comparative study between cefuroxime, ceftriaxone and amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia].
abstract: Among community-acquired infections, pneumonia is still a large health problem which is of great interest mainly due its high mortality and morbidity. From 1991 to 1997, 409 patients who had been diagnosed with community-acquired pneumonia and had been admitted to the internal medicine service of a university hospital were prospectively studied. The patients were classified into three groups according to the random antibiotic treatment they had received (ceftriaxone, cefuroxime or amoxicillin-clavulanic acid). The initial characteristics of the patients with regard to epidemiology, clinical description and critical situation were similar in all the groups studied. A total of 36.9% of the cases were documented microbiologically, with the most frequently isolated pathogens being Streptococcus pneumoniae and Haemophilus influenzae. The recovery rate was 92.2% and three patients had a recurrence of pneumonia. Global mortality was 5.8%. No statistically significant differences were found in the evolution of patients treated with cefuroxime, ceftriaxone or amoxicillin-clavulanic acid, with the latter representing an empirical treatment of choice for community-acquired pneumonia.
authors.affiliation: Servicio de Medicina Interna, Unidad de Infecciosas, Servicio de Urgencias y Secciones de Neumología y Microbiología, Hospital Universitario Virgen de la Arrixaca, Murcia.
authors.forename: M E
authors.initials: ME
authors.lastname: Sánchez
authors.forename: J
authors.initials: J
authors.lastname: Gómez
authors.forename: J
authors.initials: J
authors.lastname: Gómez Vargas
authors.forename: V
authors.initials: V
authors.lastname: Baños
authors.forename: J
authors.initials: J
authors.lastname: Ruiz Gómez
authors.forename: L
authors.initials: L
authors.lastname: Muñoz
authors.forename: E
authors.initials: E
authors.lastname: Simarro
authors.forename: M C
authors.initials: MC
authors.lastname: Soto
authors.forename: M
authors.initials: M
authors.lastname: Canteras
authors.forename: M
authors.initials: M
authors.lastname: Valdés
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000627:therapeutic use*; D002443:Ceftriaxone / Q000627:therapeutic use*; D002444:Cefuroxime / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D002648:Child; D017714:Community-Acquired Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D011446:Prospective Studies
chemical_list: D002511:Cephalosporins; D019980:Amoxicillin-Potassium Clavulanate Combination; D002443:Ceftriaxone; D002444:Cefuroxime